Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT), Selecta Biosciences (NASDAQ: SELB) and Blueprint Medicines (NASDAQ: BPMC)By Carrie Williams
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lemaitre Vascular (NASDAQ: LMAT), Selecta Biosciences (NASDAQ: SELB) and Blueprint Medicines (NASDAQ: BPMC) with bullish sentiments.
Lemaitre Vascular (NASDAQ: LMAT)
In a report released yesterday, Jason Mills from Canaccord Genuity reiterated a Buy rating on Lemaitre Vascular (NASDAQ: LMAT), with a price target of $25. The company’s shares opened today at $23.55, close to its 52-week high of $24.36.
“We reiterate our BUY rating on shares of LMAT, which has been one of the best performing med-tech stocks in the entire sector over the past two years – in part due to pristine execution of its core strategy of surrounding the vascular surgeon with innovative, proprietary or best-in-class devices. Today’s acquisition of Restore Flow Allografts for $14M leverages the company’s strong direct sales channel in vascular surgery with a product that has grown ~$1.5M per year since its April 2014 launch, and is now on a $3.7M run rate. The company will see modest dilution in Q4, but we think it can be very accretive relatively quickly, while adding growth to the top-line. We remain BUY rating on LMAT and increase our target to $25, using a 4.4x EV/Sales multiple on our 2017E revenue of $102.6M (up from $98.1M). LMAT will do a fireside chat with this author at our upcoming Medical Technologies & Diagnostics Forum (MTDF) in New York City next Thursday, Nov.”
According to TipRanks.com, Mills is a 1-star analyst with an average return of -0.9% and a 52.0% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.
Currently, the analyst consensus on Lemaitre Vascular is Moderate Buy and the average price target is $21.50, representing a -8.7% downside.
In a report issued on October 27, Roth Capital also reiterated a Buy rating on the stock with a $21.50 price target.
Selecta Biosciences (NASDAQ: SELB)
“We continue to expect positive Phase 2 data for SEL-212 in severe gout 1H17, and expect minimal or no immunogenicity coupled with strong reduction in Serum Uric Acid. The Phase 2 study is enrolling n=36 patients, and is testing three doses of both a high and low dose SVP particle combined with pegsiticase, followed by 2 monthly infusions of pegsiticase alone. Prior Phase 1a/b results showed a significant reduction in uric acid levels and also dose-dependent reduction in antibodies to pegsiticase. Detailed Phase 1a/b data for SEL-212 Dec 7 and 8 Selecta will present detailed Phase 1a/b data for SEL-212 at the Immunization and Vaccines Summitt in Boston on December 7, where we look for additional details on lower immunogenicity with higher doses of SVP.”
According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -13.3% and a 33.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.
Selecta Biosciences has an analyst consensus of Moderate Buy.
Blueprint Medicines (NASDAQ: BPMC)
Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Blueprint Medicines (NASDAQ: BPMC) yesterday and set a price target of $35. The company’s shares opened today at $34.57, close to its 52-week high of $35.20.
According to TipRanks.com, Lee is ranked 0 out of 5 stars with an average return of -9.3% and a 42.9% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Actinium Pharmaceuticals, and Asterias Biotherapeutics.
Blueprint Medicines has an analyst consensus of Moderate Buy.